OXY's leadership has made the hard financial decisions in the face of adversity to strengthen its liquidity over time. OXY is a low cost operator in oil and gas
ACRX confirmed final agreement with its cornerstone client, the US Army. Sales from DSUVIA still need to pick up. But reports from doctors using DSUVIA on their
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline fo
GUANGZHOU, China, May 21, 2020 (PR Newswire Europe via COMTEX) -- Ad fraud has become one of the greatest threats facing the fast-growing global mobile ad...
GUANGZHOU, China, May 21, 2020 /PRNewswire via COMTEX/ -- GUANGZHOU, China, May 21, 2020 /PRNewswire/ -- Ad fraud has become one of the greatest threats...
It is being reported that the EPA has sent its proposed rule for mandated biofuel blending in 2021 to the White House for review. The available details on the p
Last week, Carl Icahn's hedge fund filed its 13F for the first quarter of 2020. Occidental Petroleum was one of the hedge fund's largest buys.
Dividend cuts and suspensions announced by publicly-traded firms in the United States are continuing their torrid pace through the midpoint of May 2020. Overall
Carl Icahn’s 13F portfolio value decreased from $26.18B to $18B this quarter. Occidental Petroleum and Hertz Global Holdings stakes saw substantial increases du
Aytu BioScience, Inc. (NASDAQ:AYTU) Q3 2020 Results Earnings Conference Call May 14, 2020, 04:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO
When the tide goes out you discover who's been swimming naked. The pandemic has revealed that many stocks aren't as solid as investors might have believed. This
Exxon Mobil has made two investments in groundbreaking biofuels technologies that have attracted criticism from both environmental groups and its own shareholde
A major increase in U.S. renewable diesel production capacity is currently underway, and total capacity is expected to almost septuple over the next five years.
The chances that former Celgene investors will miss out on their CVR payment linked to the BMS takeover have risen sharply as FDA rejects filing for myeloma CAR-T ide-cel
BMS and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE